Bis-choline tetrathiomolybdate - Wilson Therapeutics

Drug Profile

Bis-choline tetrathiomolybdate - Wilson Therapeutics

Alternative Names: ATN-224; Decuprate; WTX-101

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Attenuon LLC
  • Developer Attenuon; Cancer Research UK; Wilson Therapeutics
  • Class Antineoplastics; Heavy metals; Neuroprotectants; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatolenticular degeneration; Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatolenticular degeneration
  • Preclinical Amyotrophic lateral sclerosis
  • Discontinued Breast cancer; Malignant melanoma; Multiple myeloma; Prostate cancer; Solid tumours

Most Recent Events

  • 26 Jul 2018 Wilson Therapeutics has been acquired by Alexion Pharmaceuticals
  • 12 Apr 2018 Long-term extension data from a phase II trial in Wilson's disease released by Wilson Therapeutics
  • 23 Feb 2018 Bis-choline tetrathiomolybdate - Wilson Therapeutics receives Fast Track designation for Wilson's disease [PO,Tablet] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top